Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlines the biggest management challenges in neuroendocrine tumors (NETs).
Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlines the biggest management challenges in neuroendocrine tumors (NETs).
Transcript
What are the biggest management challenges in neuroendocrine tumors?
One of the bigger management challenges is access to care and access to specialists, ad that doesn’t mean that everyone needs to be managed by a NET specialist, because they absolutely don’t. But, I think all NET patients should at least be given the option of visiting with a NET specialist just to discuss the natural history of the disease and to discuss treatments that might be available, and I think also, at the time of progression, we should really try to get these patients to see a NET specialist to discuss the different treatment options out there, including clinical trials.
So, I think access to NET specialists, because there are not that many of them, is still an issue. Insurance is an issue for some agents, high copayments for certain agents. We have to see how things play out with PRRT [peptide receptor radionuclide therapy] and insurance reimbursement. But, that would be access and the financial toxicity or direct cost to the patient would be the things on the top of my mind.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More